Immune-related adverse events in patients treated with immunotherapy for locally advanced or metastatic NSCLC in real-world settings: a systematic review and meta-analysis
Explore this paper's citation graph
Summary
The findings showed that the frequency of irAEs remained stable across the two calendar periods examined in the meta-analysis, suggesting that RW data might not be able to identify a potential learning curve in detection and management of irAEs.
- Type
- article
- Published
- 2024-07-09
- Cited by
- 8
- References
- 41
- Access
- Open access
- OpenAlex
- https://openalex.org/W39045561
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:271108580
Keywords
Code (set theory), Computer science, Set (abstract data type), Programming language
References
- Randomized clinical trials--removing unnecessary obstacles.
- Nivolumab versus Docetaxel in Advanced Non-squamous Non-small Cell Lung Cancer
- Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.
- Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
- Real‐world Efficacy and Safety of Nivolumab for Advanced Non–Small‐cell Lung Cancer: A Retrospective Multicenter Analysis
- Use of nivolumab in elderly patients with advanced squamous non-small-cell lung cancer: results from the Italian cohort of an expanded access programme.
- Efficacy of Nivolumab and Pembrolizumab in Patients With Advanced Non–Small‐Cell Lung Cancer Needing Treatment Interruption Because of Adverse Events: A Retrospective Multicenter Analysis
- Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis
- Immune checkpoint inhibitors in real-world treatment of older adults with non-small cell lung cancer
- Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.
- Efficacy and Safety of Nivolumab in Previously Treated Patients With Non-Small-cell Lung Cancer: Real World Experience in Argentina.
- Efficacy and safety of immune checkpoint inhibitor monotherapy in pretreated elderly patients with non-small cell lung cancer
- First-line pembrolizumab in advanced non-small cell lung cancer patients with poor performance status.
- Real world data in the era of Immune Checkpoint Inhibitors (ICIs): Increasing evidence and future applications in lung cancer.
- Immune checkpoint inhibition for non-small cell lung cancer in patients with pulmonary tuberculosis or Hepatitis B: Experience from a single Asian centre.
- Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50%
- Immunotherapy as second‐line treatment and beyond for non‐small cell lung cancer in a single center of China: Outcomes, toxicities, and clinical predictive factors from a real‐world retrospective analysis
Cited by
- Real-World Evaluation of Immune-Related Endocrinopathies in Metastatic NSCLC Patients Treated with ICIs in Romania
- A real-world cohort study of immune-related adverse events in patients receiving immune checkpoint inhibitors
- First-line PD-1/PD-L1 inhibitors plus chemotherapy vs. chemotherapy alone in stage IIIB–IV non-squamous NSCLC: an updated meta-analysis of phase 3 RCTs
- Optimisation and validation of line-of-therapy advancement algorithms in advanced/metastatic non-small-cell lung cancer: an I-O Optimise study
- Predictive value of combined inflammatory and coagulation markers for immune-related pneumonitis in non-small cell lung cancer patients on immunotherapy: a retrospective cohort study
- Case Report: Two atypical cases of M6-like antimitochondrial antibody pattern unlinked to iproniazid
Related papers
No related papers recorded.